Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ESMO 2019 | Temporal patterns among older patients with AML

Amer Zeidan • 27 Sep 2019
ESMO 2019
Acute Myeloid Leukemia Leukemia

Amer Zeidan, MBBS, MHS, Yale Cancer Center, New Haven, CT, discusses temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukaemia (AML). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Amer Zeidan

Correlation between treatment-emergent cytopenias and clinical response with imetelstat in LR-MDS 1:10
Correlation between treatment-emergent cytopenias and clinical response with imetelstat in LR-MDS
Amer Zeidan • 5 Dec 2025
Oral decitabine plus venetoclax for older unfit patients with AML: results of a Phase II study 2:02
Oral decitabine plus venetoclax for older unfit patients with AML: results of a Phase II study
Amer Zeidan • 5 Dec 2025
Luspatercept initiated at the maximum-approved dose in transfusion-dependent LR-MDS: MAXILUS trial 1:11
Luspatercept initiated at the maximum-approved dose in transfusion-dependent LR-MDS: MAXILUS trial
Amer Zeidan • 5 Dec 2025
Ziftomenib with azacitidine and venetoclax in NPM1-mutated AML: the KOMET-007 trial 1:57
Ziftomenib with azacitidine and venetoclax in NPM1-mutated AML: the KOMET-007 trial
Amer Zeidan • 5 Dec 2025

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals